Bexarotene
Therapeutic Indications
Bexarotene is indicated for:
Cutaneous T-cell lymphoma (CTCL)
Irrespective of gender only Adults (18 years old or older)
Bexarotene is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Oral - 300 mg/m² once daily
Contraindications
Active ingredient Bexarotene is contraindicated in the following cases:
Hepatic insufficiency
No gender/age discrimination
Lactation
No gender/age discrimination
It is unknown whether bexarotene is excreted in human milk. Bexarotene should not be used in breast-feeding mothers.
Pregnancy
No gender/age discrimination
There are no adequate data from the use of bexarotene in pregnant women. Studies in animals have shown reproductive toxicity. Based on the comparison of animal and patient exposures to bexarotene, a margin of safety for human teratogenicity has not been demonstrated. Bexarotene is contraindicated in pregnancy.
If this medicinal product is used inadvertently during pregnancy, or if the patient becomes pregnant while taking this medicinal product, the patient should be informed of the potential hazard to the foetus.
Uncontrolled hypercholesterolaemia
No gender/age discrimination
Uncontrolled thyroid disease
No gender/age discrimination
Uncontrolled hypertriglyceridaemia
No gender/age discrimination
Ongoing systemic infection
No gender/age discrimination
Hypervitaminosis A
No gender/age discrimination
Pancreatitis
No gender/age discrimination